Investing in tomorrow's medicine
Mérieux Equity Partners is a global investment platform specialized in the healthcare & nutrition sector, working alongside entrepreneurs and companies with ambitious growth plan, offering them privileged access to sector-expertise and industrial network.
Ivantis announces groundbreaking 3 year results from FDA clinical trial
First device in Minimally Invasive Glaucoma Surgical (MIGS) category to demonstrate significant long-term reduction of severe major surgeries for glaucoma patients. This is the first study of any kind showing a MIGS device achieving a statistically significant reduction in secondary incisional surgery; over 70% of patients remain free of medications.
Mérieux Equity Partners teams up with ICG to acquire leading Italian generic company, DOC Generici
DOC Generici is Italy’s largest independent generic pharmaceutical company.
Inscripta expands Series C Financing Round to $105.5 million
Existing investors have agreed to contribute an additional $20 million to its previously announced Series C funding round.